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Abstract
Background: Palmitoylethanolamide (PEA) is an endogenous fatty acid amide displaying anti-inflammatory and
analgesic actions. Moreover, several data have suggested that PEA reduced inflammation and tissue injury
associated with spinal cord trauma and showed a regulatory role for peroxisome proliferator-activated receptor
(PPAR)-α signaling in the neuroprotective effect of PEA. However, several other mechanisms could explain the
anti-inflammatory and anti-hyperalgesic effects of PEA, including the activation of PPAR-δ and PPAR-γ. The aim of
the present study was to carefully investigate the exact contribution of PPAR-δ and PPAR-γ in addition to PPAR-α,
in the protective effect of PEA on secondary inflammatory damage associated with an experimental model of
spinal cord injury (SCI).
Methods: SCI was induced in mice through a spinal cord compression by the application of vascular clips (force of
24 g) to the dura via a four-level T5 to T8 laminectomy, and PEA (10 mg/kg, intraperitoneally, 1 and 6 hours after
SCI) was injected into wildtype mice and into mice lacking PPAR-α (PPAR-αKO). To deepen the ability of specific
PPAR-δ and PPAR-γ antagonists to reverse the effect of PEA, mice were administered GSK0660 or GW9662, 30
minutes before PEA injection.
Results: Genetic ablation of PPAR-α in mice exacerbated spinal cord damage, while PEA-induced neuroprotection
seemed be abolished in PPARαKO mice. Twenty-four hours after spinal cord damage, immunohistological and
biochemical studies were performed on spinal cord tissue. Our results indicate that PPAR-δ and PPAR-γ also
mediated the protection induced by PEA. In particular, PEA was less effective in PPAR-αKO, GSK0660-treated or
GW9662-pretreated mice, as evaluated by the degree of spinal cord inflammation and tissue injury, neutrophil
infiltration, proinflammmatory cytokine, inducible nitric oxide synthase expression and motor function. PEA is also
able to restore PPAR-δ and PPAR-γ expression in spinal cord tissue.
Conclusion: This study indicates that PPAR-δ and PPAR-γ can also contribute to the anti-inflammatory activity of
PEA in SCI.
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Background
Spinal cord injury (SCI) is the result of an initial physical
trauma followed by a secondary degenerative process. SCI
leads to the destruction of ascending and descending
axonal tracts that control motor, sensory and autonomic
functions. The level of SCI is an important factor because
the consequences are devastating. Patients suffer from
permanent, often lifelong motor and sensory disabilities
below the site of injury, combined with impaired basic
vital functions. Functional recovery is restricted because
axons in the central nervous system (CNS) regenerate
poorly. Post-traumatic inflammatory reaction may play an
important role in the secondary injury processes after SCI
[1,2]. In particular, the secondary damage is sustained by a
large number of cellular, molecular, and biochemical cas-
cades and a large body of data suggests the presence of a
local inflammatory response, which amplifies the second-
ary damage [3].
Nuclear receptors are ligand-dependent transcription
factors whose activation affects genes controlling vital
processes. Among them, the peroxisome proliferator-
activated receptors (PPARs) have emerged as links be-
tween lipids, metabolic diseases, and innate immunity
[4]. PPARs are activated by fatty acids and their deriva-
tives, many of which also signal through membrane
receptors, thereby creating a lipid signaling network
between the cell surface and the nucleus. There are
three known isoforms of PPARs – PPAR-α, PPAR-γ, and
PPAR-β/δ – each with different tissue specificity and
physiological function [5]. All three isoforms share com-
mon molecular structure and functional domains similar
to other nuclear receptor superfamilies. Upon ligand
binding, PPARs forms a heterodimer with the retinoic
acid receptor (RXR) and control the expression of genes
that have PPAR response elements. PPARs exhibit com-
plex ligand binding modes. PPAR C-terminal ligand
binding domains are 60 to 70% homologous with large
Y-shaped ligand binding pockets composed of three
sub-arms that display significant homology between the
subtypes. All three PPARs bind a variety of natural and
synthetic ligands, none of which completely fills the lig-
and binding pocket, and PPAR ligands can adopt differ-
ent binding modes. Many agonists, however, conform to
a standard pharmacophoric model in which ligands
comprise a hydrophilic head group that binds arm I and
a hydrophobic tail that binds arm II and/or arm III [6].
PPAR-γ, or NRIC3, plays an important role in glucose
and lipid homeostasis, inflammation, and adipocyte dif-
ferentiation [7]. This transcription factor is further regu-
lated by commonly known coactivator proteins such as
CBP/p300, the SRC family, TRAP 220 [8], and co-
repressors such as SMART, NCoR, and RIP140 [9]. The
identification of an endogenous physiological ligand for
PPAR-γ has been problematic. Most of the studies
determining the binding efficiency have been performed
in either cell-free or cell-based systems. The specificity
of compounds to act as ligands for PPAR-γ was deter-
mined by a lack of response when cells were either pre-
treated with a known antagonist of PPAR-γ or with
constructs that lacked PPAR ligand binding domain.
However, in cell-based systems it is conceivable that a
metabolite of the parent compound, not the parent com-
pound itself, might be mediating the response through
interactions with PPAR-γ. PPAR-δ activation improves
the overall metabolic profile [10]. While no PPAR-δ ago-
nists are yet approved for human use, they have been
shown to enhance fatty acid oxidation in skeletal muscle,
reduce serum triglycerides, increase serum high-density
lipoprotein cholesterol and stimulate aspects of reverse
cholesterol transport, improve glucose homeostasis, and
trigger thermogenesis and weight loss [11].
Several studies have clearly demonstrated that PPAR-α
and PPAR-γ agonists exert beneficial effects in several
experimental models of CNS injury and disease, such as
amyotrophic lateral sclerosis [12,13], Parkinson’s disease
[14,15], cerebral ischemia or hemorrhage [16,17], and
experimental autoimmune encephalomyelitis [18,19].
Recently, the presence of PPAR-α and PPAR-γ in
discrete areas of the brain and spinal cord has been
suggested [20,21].
Indeed, we have recently demonstrated using PPAR-α
knockout (PPAR-αKO) mice that endogenous PPAR-α
activity reduces the degree of development of inflamma-
tion and tissue injury events associated with spinal cord
trauma in mice, suggesting the existence of an intrinsic
anti-inflammatory mechanism mediated by PPAR-α [22].
In addition, an endogenous ligand for PPAR-γ, the cyclo-
pentanone prostaglandin 15-deoxy-Δ12,14PGJ2, which is
a metabolite of the prostaglandin D2, reduces the devel-
opment of inflammation and tissue injury associated
with spinal cord trauma [22].
In vivo administration of the saturated N-acyletha-
nolamine palmitoylethanolamide (PEA), which expli-
cates several effects on CNS such as modulating the
pentobarbital-evoked hypnotic effect [23], controlling
inflammatory pain [24], protecting against 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
neurotoxicity [25] and learning and memory impairment
in mice [26], reduces inflammation and tissue injury asso-
ciated with SCI [27] and promotes the initiation of neuro-
trophic substance after SCI [28]. While the biological
effects of PEA are well documented, the molecular
mechanisms and site of action remain under debate. In
vitro, PEA behaves as an endogenous agonist for a canna-
binoid receptor (CB)2-like receptor subtype on mast cells
[29], can inhibit gap junction formation, and modulates
GABA and 5-HT receptors. In vivo, the analgesic effect of
PEA is reversed by the CB2 antagonist SR144528 [30],
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while PPAR-α mediates the anti-inflammatory effects of
PEA in carrageenan-induced paw edema and phorbol
ester-induced ear edema, suggesting that this fatty-acid
ethanolamide may serve, like its analog OEA, as an en-
dogenous ligand for PPAR-α [31]. There is, as yet, little
direct evidence for possible interactions of PEA with
PPAR-δ or PPAR-γ in the spinal cord [32]. Our study will
investigate whether the protective and anti-inflammatory
effects of PEA observed in a compression model of SCI
are partially mediated by other PPAR isotypes, in addition
to PPAR-α. In fact, while we have recently demonstrated
that PPAR-α modulates the anti-inflammatory property of
PEA in a mouse model of inflammatory pain [33], on the
contrary Benetti and colleagues have shown that CB1,
PPAR-γ and TRPV1 receptors mediated the antinocicep-
tion induced by PEA in mice with chronic constriction in-
jury of the sciatic nerve [10].
To characterize the role of PPAR-α, PPAR-γ and PPAR-δ
in PEA-mediated anti-inflammatory and neuroprotective
activities, we performed spinal cord trauma in mice and
studied the involvement of all of PPAR isotypes in mediat-
ing acute effects of PEA on the spinal cord.
Methods
Animals
Mice (6 to 7 weeks old, 20 to 27 g) with a targeted
disruption of the PPAR-α gene (PPAR-αKO) and litter-
mate wildtype controls (PPAR-α WT) were purchased
from Jackson Laboratories (Harlan Nossan, Italy). Mice
homozygous for the Pparatm1Gonz targeted mutation
(strain name: 129S4/SvJae-Pparatm1Gonz/J) are viable, fer-
tile and appear normal in appearance and behavior. The
study was approved by the University of Messina Animal
Care Review Board. The animals were housed in a con-
trolled environment and provided with standard rodent
chow and water. Animal care was in compliance with
regulations in Italy (D.M. 116192), Europe (O.J. of E.C. L
358/1 12/18/1986), and USA (Animal Welfare Assurance
No A5594-01, U.S. Department of Health and Human
Services, Washington, D.C USA.
Surgical procedures
Mice were anesthetized with sodium pentobarbital
(50 mg/kg, intraperitoneally). A longitudinal incision
was made on the midline of the back, exposing the para-
vertebral muscles. These muscles were dissected away ex-
posing T5 to T8 vertebrae. The spinal cord was exposed
and SCI was produced by extradural compression of the
spinal cord at T6 to T7 using an aneurysm clip with a
closing force of 24 g as previously described [22]. Follow-
ing surgery, 1 ml saline was administered subcutaneously
in order to replace the blood volume lost during surgery.
During the surgery and the recovery from anesthesia, the
mice were placed on a warm heating pad and covered
with a warm towel. The mice were singly housed in a
temperature-controlled room at 27°C for a survival period
of 10 days. Food and water were provided to the mice ad
libitum. During this time period, the animals' bladders
were manually voided twice a day until the mice were able
to regain normal bladder function. In all injured groups,
the spinal cord was compressed for 1 minute. Sham-
injured animals were only subjected to laminectomy.
Spinal cord tissues were taken at 24 hours after trauma.
Tissue segments contained the lesion (1 cm on each side
of the lesion), according to counts of retrogradely labeled
neurons at the origin of distinct descending motor path-
ways and to morphometric assessments of normal residual
tissue at the injury epicenter, as previously described [28].
WT mice were randomly allocated into the following
groups: sham+vehicle group, mice were subjected to the
surgical procedures as for the above group except that
the aneurysm clip was not applied and vehicle was admi-
nistered at 1 and 6 hours after laminectomy (n = 30);
sham+PEA group, identical to sham+vehicle group ex-
cept for the administration of PEA at 1 and 6 hours after
laminectomy (n = 30); sham+ GW9662 group, identical
to sham+PEA group except for the administration of
GW9662 (1 mg/kg intraperitoneal bolus) 30 minutes
prior to vehicle (n = 30); SCI+vehicle group, mice were
subjected to SCI (n = 30); SCI+PEA group, PEA (10 mg/
kg) was given daily as an intraperitoneal injection at 1
and 6 hours after SCI (n = 30); SCI+GSK0660, identical
to the SCI+vehicle group but GSK0660 was adminis-
tered (1 mg/kg intraperitoneally) 30 minutes and 5 and
0.5 hours and after SCI (n = 30); and SCI+GSK0660
+PEA group, identical to the SCI+PEA group but
GSK0660 was administered (1 mg/kg intraperitoneally)
30 minutes prior to PEA.
PPAR-αKO mice were randomly allocated into the fol-
lowing groups: PPAR-αKO sham group, PPAR-αKO mice
were subjected to the surgical procedures as for the above
group except that the aneurysm clip was not applied and
vehicle was administered at 1 and 6 hours after laminec-
tomy (n =30); PPAR-αKO+PEA group, identical to the
PPAR-αKO sham group except for the administration of
PEA 1 and 6 hours after laminectomy (n =30); PPAR-αKO
SCI+vehicle group, PPAR-αKO mice were subjected to
SCI and vehicle was administered at 1 and 6 hours after
laminectomy (n =30); PPAR-αKO SCI+GW9662 group,
identical to the PPAR-αKO SCI+vehicle group but
GW9662 was administered (1 mg/kg intraperitoneal
bolus) 30 minutes and 5 and 0.5 hours after SCI (n =30);
PPAR-αKO SCI + PEA group, PPAR-αKO mice subjected
to SCI received PEA injection (10 mg/kg) at 1 and 6 hours
after SCI (n =30); and PPAR-αKO SCI+GW9662+PEA
group, identical to the PPAR-αKO SCI+PEA group but
GW9662 was administered (1 mg/kg intraperitoneally)
30 minutes prior to PEA.
Paterniti et al. Journal of Neuroinflammation 2013, 10:20 Page 3 of 13
http://www.jneuroinflammation.com/content/10/1/20
PEA was purchased from Tocris Bioscience (Bristol
United Kingdom, UK), dissolved in ethanol:saline (1:9),
and used at a dose of 10 mg/kg based on a previous
in vivo study [26].
GSK0660 and GW9662 were purchased from Sigma-
Aldrich (Milan, Italy) and dissolved in a 1:1:8 mixture of
ethanol:Tween80:saline. The dose of GW9662 (1 mg/kg,
intraperitoneally) and GSK0660 (1 mg/kg, intraperitone-
ally) used here was based on previous studies [34,35].
Tissue processing and histology
At the indicated time point (24 hours), spinal cords were
dissected and tissue segments containing the lesion (1 cm
on each side of the lesion) were paraffin embedded and
cut into sections 5 μm thick. The tissue segments were
fixed for 24 hours in paraformaldehyde solution (4% in
PBS 0.1 M) at room temperature, dehydrated by graded
ethanol and embedded in Paraplast (Sherwood Medical,
Mahwah, NJ, USA). Tissue sections were deparaffinized
with xylene, stained with H & E and studied using light
microscopy connected to an imaging system (AxioVision;
Zeiss, Milan, Italy). All of the histological studies were
performed in a blinded fashion. The segments of each
spinal cord at T6 to T7 vertebrae levels were evaluated by
an experienced histopathologist. The histopathological
changes of the gray matter were scored on a six-point
scale: 0, no lesion observed, 1, gray matter contained one
to five eosinophilic neurons; 2, gray matter contained 5 to
10 eosinophilic neurons; 3, gray matter contained more
than 10 eosinophilic neurons; 4, small infarction (less than
one-third of the gray matter area); 5, moderate infarction
(one-third to one-half of the gray matter area); and 6, large
infarction (more than one-half of the gray matter area).
The scores from all sections from each spinal cord were
averaged to give a final score for individual mice. All of
the histological studies were performed in a blinded
fashion.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of poly-
morphonuclear leukocyte accumulation, was determined
as previously described [36]. At the specified time follow-
ing SCI, spinal cord tissues were obtained and weighed,
and each piece was homogenized in a solution containing
0.5% (w/v) hexadecyltrimethyl-ammonium bromide dis-
solved in 10 mM potassium phosphate buffer (pH 7) and
centrifuged for 30 minutes at 20,000 × g at 4°C. An aliquot
of the supernatant was then allowed to react with a solu-
tion of tetramethylbenzidine (1.6 mM) and 0.1 mM hydro-
gen peroxide. The rate of change in absorbance was
measured spectrophotometrically at 650 nm. MPO ac-
tivity was defined as the quantity of enzyme degrading
1 μmol peroxide/minute at 37°C and was expressed in
milliunits per gram of wet tissue.
Grading of motor disturbance
All animals were gentled prior to injury so that they were
comfortable being handled and walking in the open field
apparatus. Using the Basso Mouse Scale (BMS) locomotor
rating scale [37], mice were tested prior to injury to ensure
that all animals began with a normal score of 21. Every
day post injury the mice were then scored for 4 minutes
by two blind observers for all the treatment groups. Scores
for each hindlimb were averaged, and then used to create
group means at each day. Groups were compared using
two-way repeated-measures analysis of variance followed
by Bonferroni post-hoc analysis.
Measurement of TNFα and IL-1β concentration
Perilesional tissue, collected 24 hours after SCI, was
homogenized as previously described in PBS containing
2 mmol/l phenylmethylsulfonyl fluoride (PMSF) (Sigma
Chemical Co. Milan, Italy and tissue TNFα and IL-1β
levels were evaluated. The assay was carried out by using
an ELISA colorimetric kit (eBioscience San Diego, CA
USA according to the manufacturer’s instructions. All
TNFα and IL-1β determinations were performed in du-
plicate serial dilutions.
Western blot analysis
Spinal cord tissues, obtained from mice 24 hours after SCI
or vehicle injection, were disrupted by homogenization on
ice in lysis buffer (HEPES 20 mm, pH 7.9; 420 mm NaCl;
1.5 mm MgCl2; 1 mM ethylene glycol-bis(β-aminoethyl
ether)-N,N,N0,N0-tetraacetic acid; 0.2 mM ethylenediamine
tetraacetic acid; 25% (vol/vol) glycerol; 0.5% Nonidet P-40;
0.5 mM PMSF; 1.5 μg/ml trypsin inhibitor; 3 μg/ml pepsta-
tin A; 2 μg/ml leupeptin; 0.1 mM benzamidine; and
0.5 mM dithiothreitol). After 1 hour, tissue total lysates
were obtained by centrifugation at 100,000 × g for 15 min-
utes at 4°C. Nuclear extracts were prepared in extraction
Buffer A containing 0.2 mM PMSF, 0.15 μM pepstatin A,
20 μM leupeptin, 1 mM sodium orthovanadate, homoge-
nized at the highest setting for 2 minutes, and centrifuged
at 1,000 × g for 10 minutes at 4°C. The pellets, containing
enriched nuclei, were re-suspended in Buffer B containing
1% Triton X-100, 150 mM NaCl, 10 mM Tris–HCl pH
7.4, 1 mM ethylene glycol-bis (β-aminoethyl ether)-N,N,N0,
N0-tetraacetic acid, 1 mM ethylenediamine tetraacetic acid,
0.2 mM PMSF, 20 μM leupeptin, 0.2 mM sodium orthova-
nadate. After centrifugation for 30 minutes at 15,000 × g at
4°C, the supernatants containing the nuclear protein were
stored at −80°C for quantifying nuclear expression of
PPAR-γ and PPAR-δ. The protein concentrations were
estimated by the Bio-Rad protein assay (Bio-Rad Labora-
tories, Segrate, Milan, Italy) using BSA as standard. Seventy
micrograms of proteins were dissolved in Laemmli’s sam-
ple buffer, boiled for 5 minutes, and subjected to SDS-
PAGE (8% polyacrylamide). The blot was performed by
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transferring proteins from a slab gel to nitrocellulose mem-
brane at 240 mA for 40 minutes at room temperature
using TRANS-BLOTW SD Semy-dry Transfer Cell (BIO-
RAD Laboratories Milan, Italy ). The filters were blocked
with 1× PBS, 5% (w/v) nonfat dried milk for 40 minutes at
room temperature and subsequently probed with specific
antibodies anti-inducible nitric oxide synthase (anti-
iNOS, 1:2,000; Transduction Laboratories, California
USA), PPAR-γ (1:500; Novus Biologicals, Littleton, CO,
USA), and PPAR-δ (1:500; Santa Cruz Biotechnology, Santa
Cruz, CA, USA ) in 1× PBS, 5% w/v nonfat dried milk,
0.1% Tween-20 at 4°C, overnight. Membranes were incu-
bated with peroxidase-conjugated bovine anti-mouse IgG
secondary antibody (1:5,000; Jackson ImmunoResearch,
West Grove, PA, USA) for 1 hour at room temperature.
To ascertain that blots were loaded with equal amounts
of protein lysates, they were also incubated in the presence
of the antibody against β-actin or lamin (1:10,000; Sigma-
Aldrich Corp.). Signals were detected with enhanced
chemiluminescence detection system reagent according to
the manufacturer’s instructions (SuperSignal West Pico
Chemiluminescent Substrate; Pierce Thermo Scientific
Rockford, IL USA). The relative expression of the protein
bands of iNOS (~125 kDa), PPAR-γ (~55 kDa), and
PPAR-δ (~52 kDa) was quantified by densitometry with
ImageQuant TL software (GE Healthcare Milan Italy and
standardized for densitometric analysis to housekeeping
gene levels. Images of blot signals were imported to analysis
software (Image Quant TL, v2003; Sunnydale, CA, USA). A
preparation of commercially available molecular weight
markers (Precision Plus Protein Kaleidoscope standards;
BIO-RAD) consisting of proteins of molecular weight 10 to
250 kDa was used to define molecular weight positions and
as reference concentrations for each molecular weight.
Statistical analysis
All values in the figures and text are expressed as the
mean ± standard error of the mean of n observations.
For the in vivo studies, n represents the number of ani-
mals studied. In the experiments involving histology, the
figures shown are representative of at least three experi-
ments performed on different experimental days. The
results were analyzed by one-way analysis of variance
followed by a Bonferroni post-hoc test for multiple com-
parisons. P <0.05 was considered significant. BMS scale
data were analyzed by the Mann–Whitney test and con-
sidered significant when P <0.05.
Results and discussion
Role of functional PPAR-α gene in the protective and anti-
inflammatory properties of PEA on the degree of spinal
cord trauma
As PPAR-α is constitutively expressed in astrocytes and
neurons, it has been proposed that PPAR-α regulates brain
and spinal cord lipid homeostasis during physiological
conditions. PPAR-α activation may improve fatty acid
mobilization, supporting both functional modification and
structural reorganization in the dorsal horn of the spinal
cord, such as activation of the arachidonate cascade,
or axon sprouting. Spinal cords from non-injured mice
appeared normal by gross and microscopic examination
(Figure 1A,D). Twenty-four hours after the trauma, intra-
parenchymal hemorrhages and cell swelling were visible
throughout the white matter of injured cords (Figure 1B,E,
see histological score I), but not in sham-operated mice.
We found widespread damage to the spinal cord in H &
E-stained sections taken through the centre of injury at
T6 to T7 in PPAR-αΚΟ mice (Figure 1B,I). PPAR-α
deletion increased spinal cord edema, which is a well-
recognized cause of secondary neuronal damage after SCI
in humans and animals. The genetic absence of the PPAR-
α in KO mice significantly reduced the effect of the PEA
treatment (Figure 1C,I).
Involvement of PPAR-δ and PPAR-γ in the protective
effects of PEA during SCI
PEA post-treatment (10 mg/kg) limited SCI-induced
cytotoxic edema and infiltration of inflammatory cells
(Figure 1F,I). Co-administration of GW9662 (1 mg/kg),
a potent PPAR-γ antagonist, attenuated PEA-induced
protection observed after SCI (Figure 1G,I). Similarly,
co-administration of GSK0660 (1 mg/kg), a PPAR-δ an-
tagonist, blocked the effect of PEA post-treatment on se-
verity of damage.
Role of PPAR-α, PPAR-δ, and PPAR-γ in PEA-induced
inhibition of polymorphonuclear neutrophil infiltration
The histological pattern of SCI appeared to correlate
with the influx of leukocytes into the spinal cord. The
results of the assay for the quantization of neutrophil
influx by MPO activity shown in Figure 2 revealed that
this peroxidase was increased in the spinal cord (T6 to
T8 tract) from SCI mice 24 hours after the injury. Deter-
mination of spinal cord MPO revealed higher levels in
the injured spinal cord from PPAR-αKO mice 1 day post
lesion as compared with the WT SCI group. On the
contrary, treatment with PEA (1 and 6 hours after SCI)
resulted in a significant inhibition of the upregulation of
MPO activity. The genetic absence of the PPAR-α sig-
nificantly reduced the effect of the PEA on the neutro-
phil influx following experimental compression-type
spinal cord trauma. Moreover, co-administration of po-
tent PPAR-γ antagonist also significantly reduced the
effect of the PEA treatment on MPO (Figure 2). The
PPAR-δ receptor antagonist, GSK0660, was able to block
the effect of PEA on MPO activity. All of the antagonists
employed, when administered alone to SCI mice, did not
affect this parameter.
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Figure 1 (See legend on next page.)
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Role of PPAR-α, PPAR-δ, and PPAR-γ in PEA-induced
inhibition of spinal TNFα and IL-1β
Proinflammatory cytokines present in the CNS could
potentially regulate the expression of the CB2 receptor
on microglial cells, astrocytes, and mast cells, whose ex-
pression level is likely to be important in the regulation
of inflammation in the CNS during autoimmunity. De-
termination of TNFα and IL-1β levels by ELISA revealed
high levels in the spinal cord (L6 to L7 tract) of SCI
mice 24 hours post lesion as compared with sham ani-
mals (Figure 3A,B). Administration of PEA restored
physiological TNFα and IL-1β levels (Figure 3). Spinal
cord TNFα and IL-1β levels were significantly higher in
PPAR-αΚΟ SCI mice in comparison with the WT SCI
group (Figure 3). The genetic absence of the PPAR-α re-
ceptor significantly blocked the effect of the PEA on the
production of proinflammatory cytokines. Similarly, ei-
ther pretreatment with GSK0660, the specific PPAR-δ
antagonist, or pretreatment with GW9662, the selective
PPAR-γ receptor antagonist, reversed PEA-induced re-
duction of these cytokines.
Involvement of all of three isotypes of PPAR in iNOS
expression in the spinal cord
iNOS expression is proposed to influence the outcome
of the synaptic plasticity process in the spinal cord.
Western blot analysis of the spinal cord using an iNOS-
specific antibody showed that iNOS expression in mice
tissues was increased after spinal cord compression
(Figure 4A). PEA attenuated iNOS expression in injured
WT mice (Figure 4), contributing to neuroprotection in
a compressive model of SCI, while PEA was not able to
reduce the expression of this NOS isozymes in the
PPAR-αKO SCI group (Figure 4A). However, in PPAR-
αKO SCI animals, levels of iNOS protein in the spinal
cord were higher than that of WT SCI mice. Moreover,
either pretreatment with GSK0660, the specific PPAR-δ
antagonist, or pretreatment with GW9662, the selective
PPAR-γ receptor antagonist, did reverse PEA-induced
downregulation of iNOS (Figure 4B).
Effects of PEA on spinal PPAR-γ and PPAR-δ expression
PPAR-δ could participate to the transcriptional regulation
of oligodendrocyte differentiation, and should regulate
myelinogenesis by modulation of fatty acid metabolism.
Western blot analysis shows that PPAR-γ (Figure 5A) and
PPAR-δ (Figure 5B) were expressed in uninjured spinal
cords (Figure 5). Twenty-four hours after SCI, PPAR-γ
and PPAR-δ protein expression was significantly reduced
in spinal cord homogenates. PEA treatment significantly
restored the basal levels of spinal PPAR-γ and PPAR-δ.
Role of PPAR-α, PPAR-δ, and PPAR-γ in PEA-induced
reduction of motor dysfunction
Traumatic SCI results in severe inflammation and
decreased cellular regeneration, which lead to difficult
functional recovery. Open field locomotor function was
tested using the BMS starting 1 day post injury through
the end of the study (10 days). While motor function
was only slightly impaired in sham-operated mice, WT
mice subjected to SCI displayed significant deficits in
hind limb movement (Figure 6). In contrast, a significant
(See figure on previous page.)
Figure 1 Involvement of peroxisome proliferator-activated receptors on the protective actions of PEA following spinal cord trauma.
Following spinal cord compression a significant damage to the spinal cord from wildtype (WT) mice (E) at the perilesional zone was observed by
H & E staining when compared with spinal cord tissue collected from the sham group (D). The absence of the peroxisome proliferator-activated
receptor (PPAR)-α gene significantly increases the extent and severity of the histological damage (B) when compared with the sham group (A).
Treatment with palmitoylethanolamide (PEA, 10 mg/kg) resulted in a significant decrease in the extent and severity of damage (F). The genetic
absence of the PPAR-α receptor significantly blocked the effect of the PEA treatment (C). Pretreatment with GW9662 (1 mg/kg (G)) or GSK0660
(1 mg/kg (H)) counteracted the actions of PEA. The histological score (I) was made by an independent observer. These figures are representative
of at least three experiments performed on different experimental days. Data are mean ± standard error of the mean of 10 mice for each group.
*P <0.05 vs. sham WT; **P <0.01 vs. sham WT; #P <0.05 vs. spinal cord injury (SCI) WT.
Figure 2 Effect of PPAR-γ and PPAR-δ antagonist on the
palmitoylethanolamide-induced decrease of myeloperoxidase
activity. Myeloperoxidase (MPO) activity was significantly increased
in spinal cord injury (SCI) wildtype (WT) mice in comparison with
respective control. Treatment with palmitoylethanolamide (PEA, 1
and 6 hours after injury) significantly reduced the neutrophil influx.
The genetic absence of the peroxisome proliferator-activated
receptor (PPAR)-α receptor significantly increased the activity of this
peroxidase and blocked the effect of PEA. Pretreatment with
GSK0660 (1 mg/kg) or GW9662 (1 mg/kg) neutralized the effect of
PEA. Data are mean ± standard error of the mean of 10 mice for
each group. *P <0.05 vs. WT sham; **P <0.01 vs. WT sham; #P <0.05
vs. SCI WT group.
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worsened of hind limb motor disturbances was observed
in the PPAR-αKO operated mice (Figure 6A). PEA treat-
ment caused a significant increase in BMS scores
(Figure 6A). The genetic absence of the PPAR-α receptor
significantly blocked the effect of the PEA treatment
(Figure 6A). Similarly, when we antagonized the PPAR-δ
pathway using GSK0660, and PPAR-γ using GW9662,
we found a worse locomotor function versus PEA group
(Figure 6B).
Conclusions
Our findings confirm that PPAR-α is involved in protect-
ive effects of PEA in spinal cord trauma. Moreover, the
anti-inflammatory effect elicited by PEA was antago-
nized by the administration of the antagonists for PPAR-
γ, and PPAR-δ receptors, highlighting the involvement
of such receptors in PEA-induced protective effects of
spinal cord trauma. PPARs are constitutively expressed
in the lumbar and thoracic spinal cord of healthy ani-
mals. Activation of transcription factors is often an early
molecular event preceding long-term changes in tissue
function. While PPAR-α expression was weak in the gray
matter, a high expression was observed in some cells in
the white matter, especially in astrocytes. The presence
of PPAR-α in astrocytes suggests that this isoform mod-
ulates central inflammation, possibly by regulation of
cytokine production by astrocytes [38]. In the spinal
white matter, both PPAR-α and PPAR-δ isoforms were
expressed, but the cellular characterization using glial
cells markers revealed their different cellular distribu-
tion. A high PPAR-δ expression was present in neurons,
in the deep laminae of the dorsal horn, in the medial
and central regions of the ventral horn, in the large
motoneurons of the lamina IX and in the area X around
the central canal of the spinal cord gray matter, in all
cord segments, cervical, thoracic, or lumbar, studied.
Moreover, PPAR-δ is present in oligodendrocytes, which
are the major lipid producing cells in the nervous system
and are responsible for myelination [39]. Several data
have been reported showing that the anti-inflammatory
effects of PEA result from its ability to activate PPAR-α-
dependent gene transcription [31] and occur with a time
lag of hours [40]. Often these slow-onset actions are
preceded, however, by rapid antinociceptive responses
whose time course is incompatible with a transcription-
dependent process [41,42]. Even though PEA does not
bind to PPAR-γ, its neuroprotective actions in SCI but also
in controlled cortical impact [43] are prevented by the
PPAR-γ antagonist GW9662. Moreover, we found that a
PPAR-γ antagonist chemically unrelated to GW9662, the
compound T0070907, also affected the response to PEA
(data not shown). In addition to classical regulation of
PPAR-γ activity by ligands, PPARγ transcriptional activity
can be affected by post-translational modifications such as
cross-talk with kinases and phosphatases and its inter-
action with other proteins in the cytoplasm that leads to
nongenomic functions of PPAR-γ [44].
PPAR-α regulates systemic inflammation by inducing the
expression of anti-inflammatory proteins, and repressing
the expression of proinflammatory proteins, such as TNFα,
and limiting the recruitment of immune cells to inflamma-
tion sites [45]. PPAR-α might regulate adaptive response to
tissue injury by dampening inflammation through a slow-
onset genomic mechanism. The first report of an anti-
inflammatory activity of PEA was made by Coburn and
colleagues in 1954 [46], but the anti-inflammatory effects
of PEA may not be restricted to mast cells alone. PEA
decreased the levels of the cytokine TNFα [47]. The same
authors observed a similar inhibitory effect of PEA on
IL-4, IL-6 and IL-8 release from human peripheral blood
mononuclear cells [48]. More recently, Ross and colleagues
Figure 3 Role of peroxisome proliferator-activated receptors in
palmitoylethanolamide-induced TNFα and IL-1β inhibition after
spinal cord trauma. Wildtype (WT) mice showed a significant
production of cytokines 24 hours after spinal cord compression (A),
(B). Cytokine levels were enhanced in peroxisome proliferator-
activated receptor (PPAR)-αKO mice when compared with the spinal
cord injury (SCI) WT group. Treatment with palmitoylethanolamide
(PEA, 10 mg/kg) significantly reduced the spinal cord TNFα (A) and
IL-1β (B) production. The genetic absence of the PPAR-α receptor, as
well as GSK0660 or GW9662 pretreatment, significantly blocked this
reduction. Data are mean ± standard error of the mean of 10 mice
for each group. *P <0.05 vs. sham WT; **P <0.01 vs. sham WT group;
#P <0.05 vs. SCI WT group.
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reported that PEA reduced nitric oxide release from
RAW264.7 macrophage cells in response to lipopolysac-
charide by a CB-independent mechanism [49]. PEA has
been shown to be effective in several experimental models
of inflammation, both of immunogenic and neurogenic
origin [40,50]. Despite its various described pharmaco-
logical properties, the cellular/receptor mechanism res-
ponsible for the actions of PEA is still debated. The first
hypothesis on the mechanism of action of PEA was formu-
lated when Aloe and colleagues [51], introducing the ALIA
acronym (Autacoid Local Inflammation Antagonism),
indicated that some endogenous N-acylethanolamines,
such as PEA, exerted a local antagonism on inflammation
[51]. Moreover, various studies have hypothesized that
PEA may act via indirect interaction with CB2 receptors
[30,52,53]. In fact, it has been shown that the use of
SR144528, a CB2 specific receptor antagonist, eliminated
the antinociceptive effects of PEA [41,50,54,55]. PEA was
then found able to potentiate the effect of anandamide on
CB or vanilloid receptor (VR1) [56,57], the so-called entou-
rage effect. Considering the known changes of endocanna-
binoid system in the lesioned spinal cord (increase in 2-AG
Figure 4 Role of PPAR-α, PPAR-γ, and PPAR-δ in palmitoylethanolamide-induced inhibition of inducible nitric oxide synthase
expression. Spinal cord injury (SCI) induced an increase in inducible nitric oxide synthase (iNOS) expression evaluated by western blot analysis.
Palmitoylethanolamide (PEA) post-treatment significantly reduced the levels of this protein in spinal cord homogenates. Either pretreatment with
GW9662 (1 mg/kg) or GSK0660 (1mg/kg) counteracted the anti-inflammatory action of PEA (A). Mice with genetic absence of the peroxisome
proliferator-activated receptor (PPAR)-α receptor exhibited increased expression of iNOS when compared with that observed in the SCI wildtype
(WT) group and PEA was not able to reduce the expression of this enzyme in injured PPAR-αKO mice (B). *P <0.05 vs. sham WT; **P <0.01 vs.
sham WT group; ##P <0.01 vs. SCI WT group.
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and CB2, decrease in CB1 levels), PEA may indirectly regu-
late CB receptors expression through the increase in
endocannabinoid tone [43] or the modulation of proin-
flammatory cytokines. Indeed, CB2 receptors would play a
crucial role in limiting the spreading of this neuroinflam-
matory process [58]. In the present study we show that
the absence of PPAR-α, in PPAR-αKO mice, as well as the
use of PPAR-δ and PPAR-γ antagonist, results in a
reduced anti-inflammatory action of PEA in an experi-
mental model of SCI. Part of our results are in agreement
with previous observations indicating that PPAR-αKO
mice are more susceptible to induction of SCI, possibly
due to a less efficient anti-inflammatory control exerted
by endogenous PPAR-α ligand [59-61]. But in this paper
we show that also PPAR-δ and PPAR-γ can be involved in
the neuroprotective and anti-inflammatory effects of PEA.
Recent evidence shows that PPAR agonists prevent neur-
onal damage and myelin loss other than pain behavior in a
model of SCI [22,25,34,60]. The anti-inflammatory efficacy
of PEA resides in part in the capability to counter NF-κB
activation, the production of cytokines relevant to the in-
flammatory process including TNFα, the induction of
iNOS and cyclooxygenase-2 as well the increase in their
enzymatic activity [62,63].
Recently, Citraro and colleagues showed antiepileptic
action of PEA through CB1 and PPAR-α receptor activa-
tion in a genetic model of absence epilepsy [64].
The results described here clearly indicate that the
anti-inflammatory and protective efficacies of PEA treat-
ment are favored by the presence of PPAR-α, PPAR-δ,
and PPAR-γ.
The efficacy of PEA treatment in inflammatory and
neurological diseases may become an important therapeutic
target, and is necessary better understand the molecular
mechanisms by which PEA therapy could be act. Results
discussed here suggest a new mechanism contributing to
Figure 6 Effects of GSK0660 and GW9662 treatment on
palmitoylethanolamide-induced improvement of locomotion
after spinal cord injury. The degree of motor disturbance was
assessed every day until 10 days after spinal cord injury (SCI) by
Basso Mouse Scale (BMS) criteria. Palmitoylethanolamide (PEA)
treatment (10 mg/kg) caused a significant increase in Basso, Beattie
and Bresnahan (BBB) locomotor rating scale. Pretreatment with
GSK0660 (A) or GW9662 (B) abolished PEA-induced improvement of
locomotion after SCI. Overall BBB scores of injured PPAR-αKO mice
(B) were lower than injured WT mice (A). PEA-treated PPAR-αKO
mice did not show a recovery of locomotor function (B).
Figure 5 Effect of palmitoylethanolamide-on PPAR-γ and PPAR-δ expression. Spinal cord injury (SCI) induced a decrease of both PPAR-γ (A)
and PPAR-δ (B) expression when compared with control group, evaluated by western blot analysis. Palmitoylethanolamide (PEA) post-treatment
significantly restore the levels of both PPAR-γ (A) and PPAR-δ (B) in spinal cord homogenates. ***P <0.05 vs. sham; ###P <0.01 vs. SCI group.
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determining the full PEA efficacy and suggest future studies
should aim to analyze the possible relevance of PPAR-δ and
PPAR-γ in other human inflammatory diseases. This sug-
gests that PPAR-γ and PPAR-δ are also targets for PEA in
protecting the spinal cord against proinflammatory insults.
Since the actions of PEA were not through direct inter-
action with nuclear PPAR-γ and PPAR-δ, they are more
probably mediated primarily by CB1-dependent changes in
PPAR expression. In fact, PEA may also be able to restore
neuroinflammation-induced downregulation of PPAR-γ ex-
pression through a CB1 receptor-dependent pathway. PEA
binds to Gi-coupled CB1 receptors and/or CB2 receptors,
and their activation suppresses phosphorylation of NF-κB
through ERK/p38 mitogen-activated protein kinase and
increases the expression of PPAR-γ, which represses inflam-
matory gene transcription [65,66].
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